Vobarilizumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6R |
| Identifiers | |
| CAS Number | 1628814-88-9 |
| ATC code | none |
| Chemical data | |
| Formula | C1118H1757N315O364S8 |
| Molar mass | 256.9 kDa |
Vobarilizumab (INN) is a humanized monoclonal antibody designed for the treatment of inflammatory autoimmune diseases.[1][2]
This drug was developed by Ablynx NV.
References[edit]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab, American Medical Association.
- ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
